Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07624513 | D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM | not yet recruiting | Phase 3 | 720 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07740486 | A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease(TiTan) | not yet recruiting | Phase 3 | 248 | Polish Myeloma ConsortiumOTHER |
| 0 |
| Jul 31, 2026 |
| clinicaltrials |
| NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).(DURGA-6) | not yet recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT07732712 | Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | not yet recruiting | Phase 2 / Phase 3 | 15 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 13 | Jul 27, 2026 | clinicaltrials |
| NCT07671287 | GMMG-HD11/DSMM XXI/64007957MMY3010(AugMMent) | not yet recruiting | Phase 3 | 399 | University of Heidelberg Medical CenterOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07569757 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | not yet recruiting | Phase 3 | 280 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06580223 | Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | not yet recruiting | Phase 3 | 530 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06895512 | A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | not yet recruiting | Phase 3 | 386 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06742138 | To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma | not yet recruiting | Phase 3 | 284 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06314698 | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | not yet recruiting | Phase 3 | 478 | RenJi HospitalOTHER | 0 | Mar 18, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials